Press Releases for DRRX

Press Releases
DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R)
DURECT Announces License of ADHD Drug Candidate in Selected Asian and South Pacific Countries to Orient Pharma
DURECT Corporation Announces Second Quarter 2009 Financial
DURECT to Present at the BMO Capital Markets Healthcare Conference
DURECT Corporation Invites You to Join Its Second Quarter 2009 Earnings Conference Call
REMOXY(R) NDA Update
DURECT Appoints Dr. Joseph Stauffer as Chief Medical Officer and Executive Vice President, Corporate Strategy
DURECT Corporation Announces First Quarter 2009 Financial Results
DURECT Corporation Invites You to Join its First Quarter 2009 Earnings Conference Call
DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
DURECT to Participate in Cowen and Company Healthcare Conference
Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
Zacks Analyst Blog Highlights: Durect Corp., Alpharma, Journal Communications, Inc., Alexion Pharmaceuticals Inc. And Procter & Gamble.
DURECT Corporation Announces Fourth Quarter and Year End 2008 Financial Results
DURECT Corporation Invites You to Join Its Fourth Quarter 2008 Earnings Conference Call
Zacks Analyst Blog Highlights: Durect Corp., BT Group Plc, Canon Inc., Cosan Limited, and VimpelCom
DURECT Corporation to Participate in Upcoming Healthcare Conferences - Nov 26 2008 10:31AM
Zacks Analyst Blog Highlights: NovaMed, Inc., RC2 Corp., Durect Corp., P.T. Telekomunikasi Indonesia Tbk and Embotelladora Andina S.A.
DURECT Corporation Announces Third Quarter 2008 Financial Results
DURECT's Collaboration With Alpharma Clears HSR Review and Is Effective
Alpharma Reports Third Quarter 2008 EPS of $0.10
DURECT Corporation to Participate in Upcoming Healthcare Conferences - Oct 28 2008 9:08AM
DURECT Corporation Invites You to Join Its Third Quarter 2008 Earnings Conference Call
Zacks Analyst Blog Highlights: Johnson & Johnson, CarMax, Inc., Rackable Systems, Inc., DURECT Corp. And Alpharma Inc.
Alpharma to Develop and Commercialize DURECT's ELADUR(TM) Pain Patch
Alpharma Licenses Durect's Novel Bupivacaine Patch
DURECT Corporation Presenting at the 2008 UBS Global Life Sciences Conference
DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) Technology
REMOXY(R) NDA Filing Accepted by FDA and Priority Review Granted
DURECT Corporation Announces Second Quarter 2008 Financial Results
DURECT Corporation Invites You to Join Its Second Quarter 2008 Earnings Conference Call
ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
DURECT's Convertible Notes Exchange into Equity at Maturity
Wall Street Media Presents Five Exclusive Videos from the Needham Biotech Conference
New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone)
DURECT Corporation to Participate in Upcoming Healthcare Conferences - Jun 6 2008 9:33AM
DURECT Corporation Presenting at the 2008 UBS Global Generic and Specialty Pharmaceuticals Conference - May 27 2008 1:00AM
DURECT Corporation Announces First Quarter 2008 Financial Results - Jun 1 2008 8:16PM
DURECT Corporation Invites You to Join Its First Quarter 2008 Earnings Conference Call
DURECT to Participate in Morgan Stanley Global Healthcare Conference
DURECT Provides Update on CHRONOGESIC(R) Research Program